Asset Details
Do you wish to reserve the book?
Mucosal implications of oral Jak3-targeted drugs in COVID patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Mucosal implications of oral Jak3-targeted drugs in COVID patients
Do you wish to request the book?
Mucosal implications of oral Jak3-targeted drugs in COVID patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Mucosal implications of oral Jak3-targeted drugs in COVID patients
2025
Overview
The JAK family, particularly JAK3, plays a crucial role in immune signaling and inflammatory responses. Dysregulated JAK3 activation in SARS-CoV-2 infections has been associated with severe inflammation and respiratory complications, making JAK inhibitors a viable therapeutic option. However, their use raises concerns regarding immunosuppression, which could increase susceptibility to secondary infections. While long-term adverse effects are less of a concern in acute COVID-19 treatment, patient selection and monitoring remain critical. Furthermore, adverse effects associated with oral JAK3 inhibitors necessitate the exploration of alternative strategies to optimize therapeutic efficacy while minimizing risks. This review highlights the role of JAK3 in immune and epithelial cells, examines the adverse effects of oral JAK3 inhibitors in COVID-19 and other treatments, and discusses alternative therapeutic strategies for improving patient outcomes.
Publisher
BioMed Central,Springer Nature B.V,BMC
Subject
/ Antiviral Agents - administration & dosage
/ Antiviral Agents - adverse effects
/ Antiviral Agents - therapeutic use
/ Biomedical and Life Sciences
/ COVID-19
/ Humans
/ Jak3
/ Janus Kinase 3 - antagonists & inhibitors
/ Janus Kinase Inhibitors - administration & dosage
/ Janus Kinase Inhibitors - adverse effects
/ Janus Kinase Inhibitors - therapeutic use
/ Kinases
/ Lungs
/ Proteins
/ Review
